Technical Analysis for ONCR - Oncorus, Inc.

Grade Last Price % Change Price Change
D 28.8 3.86% 1.07
ONCR closed up 3.86 percent on Friday, January 15, 2021, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong N/A Up Down
Historical ONCR trend table...

Date Alert Name Type % Chg
Crossed Above 50 DMA Bullish 0.00%
NR7 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Fell Below 50 DMA Bearish 3.86%
180 Bearish Setup Bearish Swing Setup 3.86%
Multiple of Ten Bearish Other 3.86%
Wide Bands Range Expansion 3.86%
Down 3 Days in a Row Weakness 3.86%
Older End-of-Day Signals for ONCR ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakout 1 day ago
Up 5% 1 day ago
Up 3% 1 day ago
Down 2 % 1 day ago
Down 1% 1 day ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Oncorus, Inc., a clinical stage biopharmaceutical company, focuses to develop viral immunotherapies for cancer patients. Its lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform that it is in Phase I clinical trial to treat various cancers. The company is also developing ONCR-GBM program for treating brain cancer; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. Oncorus, Inc. has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Biology Immunotherapy Cancers Cancer Immunotherapy Virotherapy Immunotherapies Therapies For Cancer Herpes Brain Cancer Oncolytics Biotech Herpes Simplex Herpes Simplex Virus Oncolytic Virus

Is ONCR a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 37.8603
52 Week Low 14.6
Average Volume 113,335
200-Day Moving Average 0.00
50-Day Moving Average 28.12
20-Day Moving Average 32.36
10-Day Moving Average 32.02
Average True Range 3.38
ADX 30.22
+DI 16.38
-DI 21.86
Chandelier Exit (Long, 3 ATRs ) 27.73
Chandelier Exit (Short, 3 ATRs ) 36.13
Upper Bollinger Band 37.23
Lower Bollinger Band 27.49
Percent B (%b) 0.13
BandWidth 30.11
MACD Line 0.49
MACD Signal Line 1.48
MACD Histogram -0.9922
Fundamentals Value
Market Cap 629.16 Million
Num Shares 21.8 Million
EPS
Price-to-Sales 0.00
Price-to-Book 17.01
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 31.79
Resistance 3 (R3) 31.57 30.36 31.29
Resistance 2 (R2) 30.36 29.60 30.47 31.12
Resistance 1 (R1) 29.58 29.13 29.97 29.80 30.96
Pivot Point 28.37 28.37 28.57 28.48 28.37
Support 1 (S1) 27.59 27.61 27.98 27.81 26.64
Support 2 (S2) 26.38 27.14 26.49 26.48
Support 3 (S3) 25.60 26.38 26.31
Support 4 (S4) 25.82